UBS Raises Omega Healthcare Investors Price Target to $56 From $52
UBS maintained its Buy rating on the REIT. The change follows its third-quarter 2026 earnings report, which included increased 2026 guidance.
UBS maintained its Buy rating on the REIT. The change follows its third-quarter 2026 earnings report, which included increased 2026 guidance.